Juvenile-onset Cclinically amyopathic dermatomyositis: An overview of recent progress in diagnosis and management

Pediatric Drugs

Volumn 12, Issue 1, 2010, Pages 23-34

  Walling, Hobart W ^a   Gerami, Pedram ^b   Sontheimer, Richard D ^c  

^a Private Practice of Dermatology   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antihistamines, therapeutic use; Betamethasone, therapeutic use; Calcinosis, treatment; Children; Clobetasol, therapeutic use; Corticosteroids, therapeutic use; Dermatomyositis, treatment; Fluocinonide, therapeutic use

Indexed keywords

ALENDRONIC ACID; ALUMINUM HYDROXIDE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; DIPHENHYDRAMINE; ETANERCEPT; FRUCTOSE BISPHOSPHATE ALDOLASE; HYDROXYCHLOROQUINE; HYDROXYZINE; IMMUNOGLOBULIN; INFLIXIMAB; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PIMECROLIMUS; PREDNISONE; PROBENECID; RITUXIMAB; SUNSCREEN; TACROLIMUS; UNINDEXED DRUG; WARFARIN; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ACUTE KIDNEY FAILURE; ANTIBODY TITER; BLOOD CLOTTING DISORDER; BONE DENSITY; CALCINOSIS; CHILL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; EARLY INTERVENTION; ELECTROMYOGRAPHY; ENZYME BLOOD LEVEL; ERYTHEMA; EXTRACORPOREAL LITHOTRIPSY; FATIGUE; FEVER; FOLLOW UP; GOTTRON PAPULE; HEADACHE; HEMOLYSIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; JUVENILE ONSET AMYOPATHIC DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MEDLINE; MORBIDITY; MORTALITY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; PHOTOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SKIN CALCIFICATION; SKIN INFLAMMATION; SKIN MANIFESTATION; SKIN PROTECTION; SYSTEMIC THERAPY; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PEDIATRICS; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIMALARIALS; CALCINOSIS; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES, INTERSTITIAL; MUSCULAR DISEASES; PEDIATRICS; SKIN;

EID: 73849091922     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/10899380-000000000-00000     Document Type: Review

References (94)

1. Sontheimer R, Provost T. Cutaneous manifestations of rheumatic diseases. 2nd ed. Philadelphia (PA): Lippincott, Williams, and Wilkins, 2004
2. Eisenstein DM, Paller AS, Pachman LM. Juvenile dermatomyositis presenting with rash alone. Pediatrics 1997; 100: 391-392
3. El-Azhary R, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 2002; 46: 560-565
4. Gerami P, Walling HW, Lewis J, et al. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157: 637-644
5. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 years. Juvenile Dermatomyositis Research Group. Rheumatology (Oxford) 2006 Oct; 45 (10): 1255-1260
6. Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000 Mar; 43 (3): 541-549
7. Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54: 3979-3987
8. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008; 47: 324-328
9. Morinishi Y, Oh-Ishi T, Kabuki T, et al. Juvenile dermatomyositis: clinical characteristics and the relatively high risk of interstitial lung disease. Mod Rheumatol 2007; 17: 413-417
10. Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 2007; 46: 1786-1791
11. Elst EF, Klein M, De Jager W, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58: 547-555
12. Li CK, Varsani H, Holton JL, et al. MHC class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31: 605-609
13. McCann LJ, Li CK, Varsani H, et al. Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis. Clin Exp Rheumatol 2007; 25: 96-98
14. Gerami P, Lewis J, Doughty L, et al. A systematic review of adult-onset clinically-amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597-613
15. Chowdhary V, Wakhlu A, Agarwal A, et al. Outcome in juvenile dermatomyositis. Indian Pediatr 2002; 39: 931-935
16. Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 505-511
17. Miyamae T, Mori M, Inamo Y, et al. Multi-center analysis of calcinosis in children with juvenile dermatomyositis [in Japanese]. Ryumachi 2003; 43: 538-543
18. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. JRheumatol 1998; 25: 1198-1204
19. Shehata R, Al-Mayouf S, Al-Dalaan A, et al. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol 1999; 17: 115-118
20. Singh S, Bansal A. Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int 2006; 26: 510-515
21. Tabarki B, Ponsot G, Prieur AM, et al. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol 1998; 2: 205-211
22. Ansell BM. Juvenile dermatomyositis. J Rheumatol Suppl 1992; 33: 60-62
23. Bowyer SL, Clark RA, Ragsdale CG, et al. Juvenile dermatomyositis: histological findings and pathogenetic hypothesis for the associated skin changes. J Rheumatol 1986; 13: 753-759
24. Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000 Apr; 105 (4 Pt 1): 794-799
25. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004; 15: 35-39
26. García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology 2004; 209: 247-248
27. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006 Jan; 117 (1) e118-28
28. Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54: 217-220
29. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135: 1522-1525
30. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18: 333-340
31. Simons FE. H1-antihistamines in children. Clin Allergy Immunol 2002; 17: 437-464
32. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005; 141: 855-859
33. Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. JAmAcad Dermatol 1984; 10: 592-600
34. Pachman LM. Juvenile dermatomyositis: a clinical overview. Pediatr Rev 1990; 12: 117-125
35. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16: 1545-1547
36. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231-1233
37. Bloom BJ, Tucker LB, Klein-Gitelman M, et al. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol 1994; 21: 2171-2172
38. Reed AM, Lopez M. Juvenile dermatomyositis: recognition and treatment. Paediatr Drugs 2002; 4: 315-321
39. Plamondon S,Dent PB. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 2000; 27: 2031-2034
40. Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 2005; 7: 441-446
41. Pachman LM, AbbottK, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148: 247-253
42. Bowyer SL, Blane CE, Sullivan DB, et al. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 882-888
43. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30: 328-334
44. Callen AM, Pachman LM, Hayford J, et al. Intermittent high dose intravenous methylprednisolone (IV pulse) prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arth Rheum 1994; 37: R10
45. Pachman LM, Callen AM, Hayford J. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methylprednisolone therapy. Arth Rheum 1994; 37: S429
46. Rockerbie NR, Woo TY, Callen JP, et al. Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 1989; 20: 629-633
47. Galliant C, Kenny P. Oral glucocorticoids and their complications. J Am Acad Dermatol 1986; 14: 161
48. Bhagat G, Chai H. Development of posterior sub-capsular cataracts in asthmatic children. Pediatrics 1974; 73: 626
49. Akikusa JD, Feldman BM, Gross GJ, et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007 Mar; 119 (3): e778-82
50. el-Dahr S, Chevalier RL, Gomez RA, et al. Seizures and blindness following intravenous pulse methylprednisolone in a renal transplant patient. Int J Pediatr Nephrol 1987 Apr-Jun; 8 (2): 87-90
51. Santiago RA, Silva CA, Caparbo VF, et al. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol 2008; 37: 40-47
52. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/ European League against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 4-13
53. Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84: 68-74
54. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 138-141
55. Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 2006; 18: 503-506
56. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebocontrolled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-1049
57. Collet E, Dalac S, Maerens B, et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231-234
58. Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-172
59. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498-2503
60. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four-year review of nine cases. Arch Dis Child 1995; 72: 25-28
61. Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol 1999 Jul; 26 (7): 457-459
62. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9: 254-262
63. Riley P, Maillard SM, Wedderburn LR, et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology (Oxford) 2004; 43: 491-496
64. Ng YT, Ouvrier RA, Wu T. Drug therapy in juvenile dermatomyositis: followup study. J Child Neurol 1998; 13: 109-112
65. Pachman LM, Fedczyna TO, Lechman TS, et al. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep 2001; 3: 379-386
66. Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33: 1802-1804
67. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNFalpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59: 159-163
68. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008 Jun; 47 (6): 877-890
69. Dinh HV, McCormack C, Hall S, et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56: 148-153
70. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007; 56: 3107-3111
71. Oliveri MB, Palermo R, Mautalen C, et al. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996; 23: 2152-2155
72. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol 1988; 124: 1721-1722
73. Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol 1993; 20: 558-560
74. Wananukul S, Pongprasit P, Wattanakrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol 1997; 38: 202-205
75. Skuterud E, Sydnes OA, Haavik TK. Calcinosis in dermatomyositis treated with probenecid. Scand J Rheumatol 1981; 10: 92-94
76. Eddy MC, Leelawattana R, McAlister WH, et al. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab 1997; 82: 3536-3542
77. Harel L, Harel G, Korenreich L, et al. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol 2001; 28: 1129-1132
78. Nakamura H, Kawakami A, Ida H, et al. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol 2006; 33: 1691-1693
79. Fuchs D, Fruchter L, Fishel B, et al. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol 1986; 5: 527-530
80. Ichiki Y, Akiyama T, Shimozawa N, et al. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol 2001; 144: 894-897
81. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001; 138: 763-766
82. Ambler GR, Chaitow J, Rogers M, et al. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 2005; 32: 1837-1839
83. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003 Mar; 62 (3): 267-269
84. Lassoued K, Saiag P, Anglade MC, et al. Failure of warfarin in treatment of calcinosis universalis. Am J Med 1988; 84: 795-796
85. Martinez-Cordero E, Lopez-Zepeda J, Choza-Romero F. Calcinosis in childhood dermatomyositis. Clin Exp Rheumatol 1990; 8: 198-200
86. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol 1998; 25: 716-720
87. Penate Y, Guillermo N, Melwani P, et al. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 2009 Jun; 60 (6): 1076-1077
88. Chan AY, Li E. Electric shock wave lithotripsy (ESWL) as a pain control measure in dermatomyositis with calcinosis cutis-old method, new discovery. Clin Rheumatol 2005; 24: 172-173
89. Grases F, Perelló J, Isern B, et al. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br JDermatol 2005 May; 152 (5): 1022-1025
90. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol 2007 Feb; 143 (2): 269-270
91. Mendelson BC, Linscheid RL, Dobyns JH, et al. Surgical treatment of calcinosis cutis in the upper extremity. J Hand Surg Am 1977; 2: 318-324
92. Shearin JC, Pickrell K. Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. Ann Plast Surg 1980; 5: 381-385
93. Downey Jr EC, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 1988; 123: 1117-1120
94. Fonder MA, Lazarus GS, Cowan DA, et al. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008; 58: 185-206